Personalised Approaches to Improving the Effect of Anti-platelet Agents: Where Do We Stand?

Clopidogrel is the most widely prescribed P2Y12 inhibitor in the world despite the development of newer and more potent agents.1,2 Clopidogrel is administered as a pro-drug and needs to be metabolised by the cytochrome P450 enzymes (particularly by CYP2C19) in order to have biological activity.3
Source: Radcliffe Cardiology - Category: Cardiology Authors: Source Type: research